Class II · Moderate risk
Moxifloxacin HCl Ophthalmic Solution
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
FDA drug recalls in 2023
Every FDA drug recall initiated in 2023, newest first, with its risk class, status and the reason the FDA recorded. Use the cause and risk filters to narrow the year down.
1,122 recalls, newest first.
Class II · Moderate risk
Midazolam Injection
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Megestrol Acetate Oral Suspension
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Lorazepam Oral Concentrate
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Lorazepam Injection
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Lidocaine Hydrochloride Oral Topical Solution
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Lidocaine HCl Jelly USP
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Lidocaine Ointment USP
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Lidocaine 2.5% & Prilocaine 2.5% Cream
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Levofloxacin Ophthalmic Solution
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Levofloxacin Oral Solution
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Levofloxacin Injection 500mg/20 mL
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Levocarnitine Oral Solution
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Levetiracetam Oral Solution 100 mg/mL
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Lactulose Solution
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Lactulose Solution
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Ketorolac Tromethamine Ophthalmic Solution
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
IC-Green (indocyanine green for injection, USP)
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Hydromorphone Hydrochloride Injection
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Hydrocortisone and Acetic Acid Otic Solution
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
HydrALAZINE HCl Injection
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Guaifenesin Oral Solution
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Guaiatussin AC Sugar-Free
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Granisetron HCl Injection
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II · Moderate risk
Gonak Hypromellose Ophthalmic Solution 25mg/mL
CGMP Deviations: Firm went out of business and could no longer continue stability studies.